ISSN 1662-4009 (online)

ey0021.2-5 | Laboratory Reference Values | ESPEYB21

2.5. Reference values for serum calcium in neonates should be established in a population of vitamin D-replete subjects

L Levaillant , A Linglart , V Gajdos , A Benachi , JC Souberbielle

Brief Summary: This prospective cohort study measured day 3 serum calcium and 25OH vitamin D (25OHD) in 1002 mother-newborn pairs to establish reference ranges in vitamin D replete babies.Calcium declines in the first days of life and is frequently measured in the neonatal nursery, not only for symptomatic newborns but also for conditions such as prematurity, low birth weight or maternal diabetes mellitus. French guidelines recommend an oral bolus of Vit...

ey0020.2-11 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.11. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study

A Juul , P Backeljauw , M Hojby , M Kawai , RJ Kildemoes , A Linglart , N Zuckerman-Levin , R Horikawa

Brief summary: This is the first multi-national phase 2 dose finding trial aimed at investigating efficacy and safety of the long acting GH (Somapacitan) with daily GH in short children born SGA. 62 GH treatment-naïve short children born SGA were enrolled in the study. Efficacy was valuated with estimated mean annualized height velocity (HV) after 26 weeks of follow-up. Somapacitan showed similar efficacy of daily rhGH. The study will be extended for further 4 years in or...

ey0020.3-10 | Advances in Clinical Practice | ESPEYB20

3.10. Neonatal and early infancy features of patients with inactivating PTH/PTHrP signaling disorders/pseudohypoparathyroidism

G Del Sindaco , J Berkenou , A Pagnano , A Rothenbuhler , M Arosio , G Mantovani , A Linglart

In Brief: Clinical symptoms of Pseudohypoparathyroidism (PHP) and related disorders present during late childhood and adulthood. This study found that newborns with this group of conditions require specific care at birth due to increased risk of neonatal complications.Commentary: Pseudohypoparathyroidism (PHP) and related disorders, newly referred to as inactivating PTH/PTHrP signalling disorders (iPPSD), are rare endocrine diseases. Their many clinical ...

ey0020.3-11 | Advances in Clinical Practice | ESPEYB20

3.11. Growth and disease burden in children with hypophosphatasia

W Hogler , A Linglart , A Petryk , PS Kishnani , L Seefried , S Fang , C Rockman-Greenberg , K Ozono , K Dahir , GA Martos-Moreno

In Brief: Hypophosphatasia is a clinically heterogenous disorder. By analysing observational data on 215 children (54.4% girls) with hypophosphatasia from the Global Hypophosphatasia Registry, the authors found growth impairment in patients aged <2 years. However, short stature was not a characteristic feature of children with hypophosphatasia, and height was not correlated with disease severity.Commentary: Hypophosphatasia is an inborn error of meta...

ey0021.5-3 | Advances in Clinical Practice | ESPEYB21

5.3. The Global ALPL gene variant classification project: dedicated to deciphering variants

Farman Mariam R , Rehder Catherine , Malli Theodora , Rockman-Greenberg Cheryl , Dahir Kathryn , Angel Martos-Moreno Gabriel , Linglart Agnes , al. et

In brief: This article describes the functionalities of the Global ALPL gene variant classification project, which aims to reclassify variants of uncertain significance (VUS) in the ALPL gene and to continuously assess and update genetic, phenotypic, and functional variant information in hypophosphatasia.Commentary: Hypophosphatasia (HPP) is a rare genetic disorder caused by loss-of-function mutations in the alkaline phosphatase ( A...

ey0015.5-1 | New and repurposed therapies | ESPEYB15

5.1 Burosumab Therapy in Children with X-Linked Hypophosphatemia

TO Carpenter , MP Whyte , EA Imel , AM Boot , W Hogler , A Linglart , R Padidela , W Van't Hoff , M Mao , CY Chen , A Skrinar , E Kakkis , J San Martin , AA Portale

To read the full abstract: N Engl J Med 2018;378:1987-1998FGF-23 is the primary regulator of phosphate homeostasis and acts by inhibiting phosphate reabsorption in the kidney (1). Loss-of-function mutations in the gene encoding phosphate-regulating endopeptidase homolog X-linked (PHEX) results in excess circulating FGF-23, which impairs renal phosphate reabsorption causing hypophosphatemia...

ey0021.5-2 | Advances in Clinical Practice | ESPEYB21

5.2. Clinical profiles of children with hypophosphatasia prior to treatment with enzyme replacement therapy: an observational analysis from the global HPP registry

Martos-Moreno Gabriel Angel , Rockman-Greenberg Cheryl , Ozono Keiichi , Petryk Anna , Kishnani Priya S. , Dahir Kathryn M. , Seefried Lothar , Fang Shona , Hogler Wolfgang , Linglart Agnes

In brief: This observational analysis, based on data from the Global Hypophosphatasia Registry, reports the clinical profiles, prior to initiation of asfotase alfa enzyme replacement therapy, in a large cohort of children with hypophosphatasia (n=151), by age (<6 months vs 6 months to 18 years) and geographic region (USA/Canada, Europe, and Japan).Commentary: Hypophosphatasia (HPP) is a rare genetic disorder caused by loss-of-function mutations in th...

ey0019.14-14 | New treatments | ESPEYB19

14.14. A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia

Zhukouskaya Volha V , Jauze Louisa , Charles Severine , Leborgne Christian , Hilliquin Stephane , Sadoine Jeremy , Slimani Lotfi , Baroukh Brigitte , van Wittenberghe Laetitia , Daniele Natalie , Rajas Fabienne , Linglart Agnes , Mingozzi Federico , Chaussain Catherine , Bardet Claire , Ronzitti Giuseppe

Science Advances, 2021,7:eabj5018 doi: 10.1126/sciadv.abj5018Brief Summary: The authors developed a liver-targeting adeno-associated virus (AAV) vector carrying C-terminal FGF23 (cFGF23) to inhibit FGF23 signalling in a mouse model for X-linked hypophosphataemic rickets (hyp-duk mice). They were able to show that a single injection of AAV cFGF23 rescued the hyp-duk phenotype.<p class="abst...

ey0016.5-12 | Clinical Guidance | ESPEYB16

5.12. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia

D Haffner , F Emma , DM Eastwood , MB Duplan , J Bacchetta , D Schnabel , P Wicart , D Bockenhauer , F Santos , E Levtchenko , P Harvengt , M Kirchhoff , F Di Rocco , C Chaussain , ML Brandi , L Savendahl , K Briot , P Kamenicky , L Rejnmark , A Linglart

Nat Rev Nephrol. 2019 May 8. doi: 10.1038/s41581-019-0152-5. [PMID: 31068690].Abstract: www.ncbi.nlm.nih.gov/pubmed/?termZ31068690In brief: In this Evidence-Based Guideline on X-linked hypophosphataemia, the authors identify the criteria for diagnosis of this disease, provide guidance for medi...

ey0020.3-4 | Advances in Clinical Practice | ESPEYB20

3.4. Skeletal and extraskeletal disorders of biomineralization

MT Collins , G Marcucci , HJ Anders , G Beltrami , JA Cauley , PR Ebeling , R Kumar , A Linglart , L Sangiorgi , DA Towler , R Weston , MP Whyte , ML Brandi , B Clarke , RV Thakker

In Brief: This is a timely and well-written review on disorders of biomineralization and their fundamental mechanisms and by leading experts in the field. This is mandatory reading for any aspiring endocrinologist.Commentary: Biomineralization is a critical physiological process, and deviations from it can cause various diseases. Recent progress has furthered our understanding of the genetic, molecular, and cellular underpinnings of the disorders of biom...